Will These 3 Dividend Stocks Impress Investors This Earnings Season?
Dan Carroll, The Motley Fool - Motley Fool - Wed Apr 23, 5:30PM CDT
Earnings season already has produced its fair share of surprises, but big pharma's hardly even broken out of the gate so far. However, a trio of major drugmakers are set to release their quarterly results in the next two weeks, and all eyes in the...
Final Glance: Pharmaceuticals companies
AP - Wed Apr 23, 5:04PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Bristol-Myers, Samsung BioLogics Extend Ties - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 4:30PM CDT
Bristol-Myers Squibb Company (BMY) expanded its existing manufacturing agreement with Samsung BioLogics.
AbbVie Files for HCV Combination Therapy in U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 4:21PM CDT
AbbVie submitted a NDA to the FDA for its investigational hepatitis C virus infection therapy.
Midday Glance: Pharmaceuticals companies
AP - Wed Apr 23, 12:37PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Wed Apr 23, 9:29AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Say Hello to the New Fastest Growing Drug in History!
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 23, 9:03AM CDT
Take every guess you had as to how well Gilead Sciences would perform in the first-quarter, no matter how outrageous, and completely throw them out the window because Gilead would have trumped it! Break out your thesaurus because you'll need...
Global T-Cell Leukemia Therapeutics Pipeline Review 2014 - Analysis of 10 Companies & 14 Drug Profiles
M2 - Wed Apr 23, 8:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/943p82/tcell_leukemia) has announced the addition of the "T-Cell Leukemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of T-Cell Leukemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for T-Cell Leukemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the T-Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the T-Cell Leukemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Kyowa Hakko Kirin Co., Ltd. - Nippon Kayaku Co., Ltd. - Pfizer Inc. - Celgene Corporation - Mundipharma International Limited - Pharmacyclics, Inc. - Stemline Therapeutics, Inc. - CytImmune Sciences, Inc. - Applied Immune Technologies Ltd Drug Profiles - mogamulizumab - forodesine hydrochloride - lenalidomide - Anti-Tac(Fv)-PE38 Immunotoxin - PF-03084014 - BMS-906024 - PCI-34051 - SL-101 - Lenaldekar - CYT-91000 - NK-314 - Immunotoxins - TCRL Antibodies For HTLV-1 - L1AD3 For more information visit http://www.researchandmarkets.com/research/94...l_leukemia
Peregrine Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Combining Its Immunotherapy Bavituximab and Ipilimumab (Yervoy(R)) in Advanced Melanoma
Marketwire - Wed Apr 23, 6:30AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced the opening of an investigator-sponsored trial (IST) of its investigational immunotherapy bavituximab in combination with Bristol-Myers Squibb's ipilimumab (Yervoy(R)), for the treatment of advanced melanoma. Bavituximab is an upstream immune checkpoint inhibitor that targets phosphatidylserine (PS), a highly immunosuppressive molecule exposed on cells that line tumor blood vessels and tumor cells. Preclinical data in a model of melanoma demonstrate that the combination of a bavituximab equivalent and ipilimumab yield enhanced anti-tumor activity compared to ipilimumab alone. The trial is being conducted at the University of Texas Southwestern Medical Center, Dallas, and led by Arthur E. Frankel, M.D., Associate Professor of Internal Medicine at the Simmons Comprehensive Cancer Center. Bavituximab, Peregrine's lead immuno-oncology candidate, is being evaluated in second-line non-small cell lung cancer (NSCLC), as part of the SUNRISE pivotal Phase III clinical trial.
Celgene to Rise Like a Phoenix: Opinion
at The Street - Wed Apr 23, 5:21AM CDT
Celgene's share price offers both growth or value investors something to like.
Bristol-Myers Squibb expands manufacturing agreement with Samsung BioLogics
M2 - Wed Apr 23, 4:13AM CDT
Biopharmaceutical company Bristol-Myers Squibb Company (NYSE:BMY) declared on Tuesday that it has extended its existing manufacturing agreement with Samsung BioLogics for an undisclosed value.
Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement
Business Wire - Tue Apr 22, 6:00PM CDT
Bristol-Myers Squibb Company (NYSE:BMY) and Samsung BioLogics today announced the companies will increase the scope of their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its Incheon manufacturing site. Financial terms of the agreement are not disclosed.
Global Synthetic Biology Market 2013-2019 - Genome Engineering, DNA Sequencing, Bioinformatics & Biological Components and Integrated Systems
M2 - Tue Apr 22, 5:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/29nxfg/synthetic_biology) has announced the addition of the "Synthetic Biology Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast,2013 - 2019" report to their offering. Synthetic biology is a synergistic combination of biology and engineering for the construction of artificial biological system in order to gain desired functions (i.e. to reduce cost or improve efficacy). It comprises nascent technologies that enable synthesis of novel biological parts and organisms that are used in the field of healthcare, chemicals, agriculture and others (biosecurity, R&D and energy and environment). The synthetic biology market is witnessing rapid growth owing to increase in demand for renewable fuels and bio-based chemicals and inexpensive drugs and vaccines that utilizes synthetic biology technologies and products. In addition, participation of various organizations such as BioBricks, DIYbio and SynBERC, for the development of synthetic biology field will further augment the growth of this market during the forecast period. However, high cost and strict regulations to use synthetic biology techniques hampers the growth of this market. Synthetic biology market is segmented mainly by products, by technologies and by applications. Synthetic biology, by product segment is classified as core products and enabling products. Core products are further segmented into synthetic DNA, synthetic genes, synthetic cells, XNA and chassis organisms. The synthetic biology market by core products was dominated by synthetic DNA market in 2012 owing to the commercial availability of this product, compared to other synthetic core products expected to be launched in the market in coming years. Synthetic biology market by technologies is segmented as genome engineering, DNA sequencing, bioinformatics and biological components and integrated systems. Genome engineering technology can be used to modify genetic foods, gene cloning and gene therapy. Thus, application of genome engineering increases the scope to utilize this technique and hence accentuates the growth of this market. Applications of synthetic biology are healthcare, chemicals, agriculture and others. Synthetic biology in healthcare holds largest market share in terms of revenue due to high utilization of synthetic biology techniques to produce cheap drugs and vaccines. Also, commercial availability of synthetic DNA and synthetic genes supports the growth of the healthcare application in the synthetic biology market. Agriculture segment is expected to grow at the highest growth rate during the forecast period. The global synthetic biology market is segmented into the following categories: Products - Core Products - - Synthetic DNA - - Synthetic Genes - - Synthetic Cells - - XNA (Xeno Nucleic Acid) - - Chasis Organisms - Enabling Products - - DNA Synthesis - - Oligonucleotide Synthesis Technologies - Genome Engineering - DNA Sequencing - Bioinformatics - Biological Components and Integrated Systems Applications - Healthcare - Chemicals (Including Bio-Fuels) - Agriculture - Others (Biosecurity, R&D, Energy and Environment) Key Topics Covered: - Introduction - Executive Summary - Market Overview - Global Synthetic Biology Market, by Products - Global Synthetic Biology Market, by Technologies - Global Synthetic Biology Market, by Applications - Global Synthetic Biology Market, by Geography - Competitive Landscape - Recommendations - Company Profiles - Agrivida, Inc. - Amyris, Inc. - Algenol Biofuels, Inc. - ATG:biosynthetics GmbH - Bayer AG - Bristol-Myers Squibb - BIONEER CORPORATION - Biosearch Technologies, Inc. - CBC Comprehensive Biomarker Center GmbH - Cobalt Technologies - DuPont, Inc. - Evolva SA - Exxon Mobil Corporation - Ginkgo Bioworks - GeneWorks Pty Ltd. - Genomatica, Inc. - GeneScript Corporation - Gevo, Inc. - Green Biologics Limited - New England Biolabs, Inc. - OriGene Technologies, Inc. - REG Life Sciences, LLC - Royal DSM - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/29...ic_biology
Pfizer, Inc. Rebuffed: Is AstraZeneca plc Worth Another Try?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
Big-time pharma mergers have had a mixed track record, with large combinations often leading to significant cost reductions (and firings) in sales and administration but at the cost of large disruptions to R&D. Pfizer is apparently not afraid...
SmarTrend Watching for Potential Pullback in Shares of Bristol-Myers Squibb After 2.12% Gain
Comtex SmarTrend(R) - Mon Apr 21, 4:13PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $49.58 to a high of $50.60. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $49.68 on volume of 5.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of Bristol-Myers Squibb to Potentially Pullback after Yesterday's 2.12% Rise
Comtex SmarTrend(R) - Mon Apr 21, 4:13PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $49.58 to a high of $50.60. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $49.68 on volume of 5.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Galectin Therapeutics Rises on GR-MD-02 Update - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 3:45PM CDT
Share price of Galectin Therapeutics jumped 12.9% after the company announced dosing of the first patient in cohort 2 of a phase I study on GR-MD-02.